Overcoming treatment resistance in cancer: Current understanding and tactics. (28th February 2017)

• Record Type: Journal Article
• Authors: Wu, Guang; Wilson, George; George, Jacob; Liddle, Christopher; Hebbard, Lionel; Qiao, Liang
• Is Part Of: Cancer letters. Volume 387(2017)
• Page Start: 69
• Page End: 76
• Publication Date: 2017-02-28
• Subjects: Treatment resistance -- Cancer stem cells -- Cancer progression -- Mutation -- EMT -- EMT transition; ABCB1 ATP-binding cassette, Sub-family B, Member 1 -- ABCG2 ATP-binding cassette, Sub-family G, Member 2 -- AKT V-Akt murine thymoma viral oncogene -- APC adenomatous polyposis coli -- AQ4N di-N-oxide aliphatic amino anthracenedione -- BRAF b-Raf proto-oncogene -- BRCA breast cancer gene -- CDK2N cyclin-dependent kinase 2 -- CSCs cancer stem cells -- EGFR epidermal growth factor receptor -- EMT epithelial to mesenchymal transition -- ER estrogen receptors -- FBXW7 f-box and WD repeat domain containing 7 -- HCC hepatocellular carcinoma -- HDAC histone deacetylase -- HIF hypoxia inducible factor -- KRAS the human homolog of the Kirsten rat sarcoma-2 virus oncogene -- MAPK mitogen-activated protein kinase -- MEK mitogen-activated protein kinase -- MMPs matrix metalloproteinase -- NF nuclear factor -- NRAS neuroblastome RAS viral oncogene: -- NSCLC non-small cell lung carcinoma -- PIK3CA phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha -- PTEN phosphatase and tensin homolog -- siRNA small interfering RNA -- SAHA suberoylanilide hydroxamic acid -- SMAD4 SMAD family member 4 -- SP side population -- TERT telomerase reverse transcriptase -- TGF-β1 transforming growth factor, beta 1 -- TIMP-2 tissue inhibitor of matrix metalloproteinase-2 -- TMZ Temozolomide -- TP53 tumor protein 53 -- ZEB1 zinc finger E-box binding homebox 1; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2016.04.018
• Languages: English
• ISSNs: 0304-3835

Abstract

Highlights: Considering many tumor recurrences after chemotherapy, treatment resistance has attracted great scientific attention. There have been some seminal discoveries, such as sequential mutations and cancer stem cells. The successful treatment of cancer still requires a considerable refinement of our knowledge concerning treatment resistance. We expect that a more informed and refined approach to treat cancer will be developed and this may improve prognosis of cancer patients. Knowledge about the failure of cancer treatments and potential approaches to overcome therapeutic resistance is discussed. Abstract: Chemotherapy is the standard treatment for many, if not all, metastatic cancers. While chemotherapy is often capable of inducing cell death in tumors leading to shrinkage of the tumor bulk, many patients suffer from recurrence and ultimately death due to resistance. During the last decade, treatment resistance has attracted great attention followed by some seminal discoveries, including sequential mutations, cancer stem cells, and bidirectional inter-conversion of stem and non-stem cancer cell populations. Nevertheless, the successful treatment of cancer will require a considerable refinement of our knowledge concerning treatment resistance. In doing so, we expect that a more informed and refined approach to treat cancer will be developed and this may improve prognosis of cancer patients. In this review, we will discuss the current knowledge concerning the failure of cancer treatments and the potential approaches to overcome therapeutic resistance.